Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ritedose Gets FDA Nod for Albuterol 0.5% to Help Address Nationwide Drug Shortage
Details : Albuterol sulfate works as a bronchodilator by activating beta-2 adrenergic receptors in the airways, leading to relaxation of smooth muscles and widening of the airways.
Product Name : Albuterol Sulfate-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 20, 2025
Lead Product(s) : Salbutamol Sulphate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ensifentrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Verona Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Ritedose Partners with Verona Pharma To Deliver COPD Drug Ohtuvayre
Details : Verona partnered with Ritedose for the development and manufacturing partner of Ohtuvayre (ensifentrine), a new novel product for Chronic Obstructive Pulmonary Disease.
Product Name : Ohtuvayre
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 17, 2024
Lead Product(s) : Ensifentrine
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Verona Pharma
Deal Size : Undisclosed
Deal Type : Partnership